Filana Therapeutics Stock Price, News & Analysis
Why is FLNA Stock Down Today?
Company Description
Filana Therapeutics (NASDAQ: FLNA) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $66.7M, ranking #5,513 among all listed U.S. companies by market cap.
FLNA stock has declined 31.1% over the past year. Shares last traded at $1.44.
On a trailing twelve-month basis, Filana Therapeutics reported net income of -$91.0M and diluted earnings per share of $-1.88.
This page provides a comprehensive overview of FLNA stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Filana Therapeutics (FLNA) stock last traded at $1.44, down 4.24% from the previous close. Over the past 12 months, the stock has lost 31.1%. At a market capitalization of $66.7M, FLNA is classified as a micro-cap stock with approximately 48.3M shares outstanding.
FLNA Rankings
Latest News
Filana Therapeutics has 5 recent news articles, with the latest published today. Of the recent coverage, 1 article coincided with positive price movement and 2 with negative movement. Key topics include earnings. View all FLNA news →
SEC Filings
Filana Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-Q, 1 Form ARS, 1 Form DEF 14A. The most recent filing was submitted on May 7, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FLNA SEC filings →
Financial Highlights
operating income reached -$95.4M, and net income was -$91.0M. Diluted earnings per share stood at $-1.88. The company generated -$32.3M in operating cash flow. With a current ratio of 2.23, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Filana Therapeutics (FLNA) currently stands at 6.9 million shares, down 4.3% from the previous reporting period, representing 16.1% of the float. This moderate level of short interest indicates notable bearish positioning. With 22.4 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Filana Therapeutics (FLNA) currently stands at 22.4 days, up 25.6% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 149.2% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 9.0 to 22.4 days.
FLNA Company Profile & Sector Positioning
Filana Therapeutics (FLNA) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Filana Therapeutics (NASDAQ: FLNA) reported Q1 2026 results and a business update on simufilam for TSC-related epilepsy on May 7, 2026. Cash was $86.6M at March 31, 2026; estimated cash at June 30, 2026 is $47–$50M. Net loss was $10.3M ($0.21/share); R&D and G&A declined year-over-year.
The company is addressing the FDA clinical hold with additional preclinical data and protocol changes and presented preclinical simufilam data at Eilat XVIII and in Epilepsia.